SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2242-2249. Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-03-066936. This Article Full Text (PDF) All Versions of this Article: blood-2007-03-066936v1 110/7/2242    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by O'Hare, T. Articles by Deininger, M. W. Search for Related Content PubMed PubMed Citation Articles by O'Hare, T. Articles by Deininger, M. W. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 21, 2007 Accepted May 7, 2007 Bcr-Abl kinase domain mutations, drug resistance and the road to a cure of chronic myeloid leukemia Thomas O'Hare, Christopher A. Eide, and Michael WN Deininger* Howard Hughes Medical Institute, Oregon Health & Science University, Portland, Oregon, United States OHSU Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States * Corresponding author; email: deininge{at}ohsu.edu. Mutations in the kinase domain (KD) of Bcr-Abl are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we examine predisposing factors underlying acquisition of KD mutations, evidence for acquisition of mutations prior to and during therapy, and whether the detection of a KD mutation universally implies resistance. We also provide a perspective on how the second-line Abl inhibitors dasatinib and nilotinib are faring in the treatment of imatinib-resistant CML, especially in relation to specific KD mutations. We discuss the growing importance of the multi-inhibitor-resistant T315I mutant and the therapeutic potential that a T315I inhibitor would have. Lastly, we assess the potential of Abl kinase inhibitor combinations to induce stable responses even in advanced CML and interpret the emerging data in the context of CML pathogenesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. J. Garg, H. Kantarjian, S. O'Brien, A. Quintas-Cardama, S. Faderl, Z. Estrov, and J. Cortes The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up Blood, November 12, 2009; 114(20): 4361 - 4368. [Abstract] [Full Text] [PDF] R. D. Press, S. G. Willis, J. Laudadio, M. J. Mauro, and M. W. N. Deininger Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood, September 24, 2009; 114(13): 2598 - 2605. [Abstract] [Full Text] [PDF] E. Jabbour, D. Jones, H. M. Kantarjian, S. O'Brien, C. Tam, C. Koller, J. A. Burger, G. Borthakur, W. G. Wierda, and J. Cortes Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations Blood, September 3, 2009; 114(10): 2037 - 2043. [Abstract] [Full Text] [PDF] T. Ernst, F. X. Gruber, O. Pelz-Ackermann, J. Maier, M. Pfirrmann, M. C. Muller, I. Mikkola, K. Porkka, D. Niederwieser, A. Hochhaus, et al. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib Haematologica, September 1, 2009; 94(9): 1227 - 1235. [Abstract] [Full Text] [PDF] M. Brehme, O. Hantschel, J. Colinge, I. Kaupe, M. Planyavsky, T. Kocher, K. Mechtler, K. L. Bennett, and G. Superti-Furga Charting the molecular network of the drug target Bcr-Abl PNAS, May 5, 2009; 106(18): 7414 - 7419. [Abstract] [Full Text] [PDF] F. Castagnetti, F. Palandri, M. Amabile, N. Testoni, S. Luatti, S. Soverini, I. Iacobucci, M. Breccia, G. Rege Cambrin, F. Stagno, et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party Blood, April 9, 2009; 113(15): 3428 - 3434. [Abstract] [Full Text] [PDF] E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF] D. Jones, S. Kamel-Reid, D. Bahler, H. Dong, K. Elenitoba-Johnson, R. Press, N. Quigley, P. Rothberg, D. Sabath, D. Viswanatha, et al. Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia: A Report of the Association for Molecular Pathology J. Mol. Diagn., January 1, 2009; 11(1): 4 - 11. [Abstract] [Full Text] [PDF] T. O'Hare and M. W. Deininger Toward a Cure For Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2008; 14(24): 7971 - 7974. [Full Text] [PDF] B. J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood, December 15, 2008; 112(13): 4808 - 4817. [Abstract] [Full Text] [PDF] E. Jabbour, H. M. Kantarjian, D. Jones, N. Reddy, S. O'Brien, G. Garcia-Manero, J. Burger, and J. Cortes Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors Blood, December 15, 2008; 112(13): 4839 - 4842. [Abstract] [Full Text] [PDF] R.T. Williams and C.J. Sherr The INK4-ARF (CDKN2A/B) Locus in Hematopoiesis and BCR-ABL-induced Leukemias Cold Spring Harb Symp Quant Biol, November 26, 2008; (2008) sqb.2008.73.039v2. [Abstract] [PDF] T. P. Hughes, S. Branford, D. L. White, J. Reynolds, R. Koelmeyer, J. F. Seymour, K. Taylor, C. Arthur, A. Schwarer, J. Morton, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy Blood, November 15, 2008; 112(10): 3965 - 3973. [Abstract] [Full Text] [PDF] P. J. Campbell, E. D. Pleasance, P. J. Stephens, E. Dicks, R. Rance, I. Goodhead, G. A. Follows, A. R. Green, P. A. Futreal, and M. R. Stratton Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing PNAS, September 2, 2008; 105(35): 13081 - 13086. [Abstract] [Full Text] [PDF] Y. Dai, S. Chen, C. A. Venditti, X.-Y. Pei, T. K. Nguyen, P. Dent, and S. Grant Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate Blood, August 1, 2008; 112(3): 793 - 804. [Abstract] [Full Text] [PDF] L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF] J. S. Khorashad, D. Milojkovic, P. Mehta, M. Anand, S. Ghorashian, A. G. Reid, V. De Melo, A. Babb, H. de Lavallade, E. Olavarria, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib Blood, February 15, 2008; 111(4): 2378 - 2381. [Abstract] [Full Text] [PDF] M. Baccarani, F. Pane, and G. Saglio Monitoring treatment of chronic myeloid leukemia Haematologica, February 1, 2008; 93(2): 161 - 169. [Full Text] [PDF] T. Ernst, P. Erben, M. C. Muller, P. Paschka, T. Schenk, J. Hoffmann, S. Kreil, P. La Rosee, R. Hehlmann, and A. Hochhaus Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib Haematologica, February 1, 2008; 93(2): 186 - 192. [Abstract] [Full Text] [PDF] M. W. Deininger Milestones and Monitoring in Patients with CML Treated with Imatinib Hematology, January 1, 2008; 2008(1): 419 - 426. [Abstract] [Full Text] [PDF] G. Saglio, F. Pane, and G. Martinelli State-of-the-art Monitoring for Patients with Chronic Myeloid Leukemia ASCO Educational Book, January 1, 2008; 2008(1): 313 - 317. [Abstract] [Full Text] [PDF] M. W.N. Deininger Imatinib Resistance and the Difficulty of Eradicating Leukemia Stem Cells ASCO Educational Book, January 1, 2008; 2008(1): 318 - 323. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] R. T. Williams, W. den Besten, and C. J. Sherr Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia Genes & Dev., September 15, 2007; 21(18): 2283 - 2287. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020